Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Fragile X Syndrome

In brief

The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.

Key facts

Study ID

NCT01254045

Run by

Stanford University

People needed

10

Starts

2007-02-01

Expected to finish

2010-01-01

Last updated by the study team

2020-03-18

Who can join

Age: 13 and older, up to 29. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).
• Male (who have more serious effects due to the X chromosome nature of the disorder)
• Age 13-29 years.
• Parent of adolescent must be willing to sign informed consent.
• Intelligence Quotient (IQ) > 42.

You may not qualify if…

• Cardiac risk factors.
• Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or atypical antipsychotics.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.